2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp - LARVOL DELTA

FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Abliva AB | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Nov 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2027

Enrollment open • Trial completion date • Trial primary completion date • Metabolic Disorders

Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease. (PubMed, Brain) - "Importantly, the data from the trial support efficacy of KL1333 based on improvements in fatigue and functional strength and endurance. Furthermore, the study highlights the value in using phase 1 studies to capture data that helps optimize later phase efficacy trial design."

Journal • P1 data • Fatigue • Gastrointestinal Disorder • Metabolic Disorders • Rare Diseases

FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Abliva AB | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Disorders

FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Abliva AB | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders

FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Abliva AB

New P2 trial • Metabolic Disorders

Efficacy of KL1333 in adult patients with primary mitochondrial disease (clinicaltrialsregister.eu) - P3 | N=180 | Ongoing | Sponsor: Abliva AB

New P3 trial • Fatigue • Metabolic Disorders • Myositis

"BioStock: Celebrating IND approval Abliva eyes next step with KL1333 https://t.co/l5Bn2eCL5o" (@CisionNews)